Shire's 2015 results beat expectations

11 February 2016

Ireland-headquartered Shire (LSE: SHPL) posted fourth quarter 2015 non-generally accepted accounting principles (GAAP) earnings per share of $2.97, up 13%, on revenue up 9% to $1.72 billion, both beating analysts' consensus of $2.87 and $1.70 billion, respectively. The firm’s shares rose 2.75% to £36.66 following the announcement this morning.

For full-year 2015, Shire generated revenues of $6.4 billion, up 7% compared with 2014, or up 11% on a currency adjusted basis. EPS was 10% higher (+14% currency adjusted) at $11.68. Analysts had expected, on average, revenues of $6.31 billion and EPS of $11.40.

However net profits were down sharply at $1.3 billion from $3.4 billion in 2014, when Shire benefited from a $1.6 billion break-up fee, when AbbVie pulled out of its tax-inversion aimed takeover of Shire.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK